Company / Operating Margin
Fulgent Genetics, Inc. Operating Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-28.2%
FY2025
5-year range
-28.2% / 68.8%
FY2021-FY2025
Trend
-8.2%
vs FY2024
Sector context
#130 of 148
Health Care
What the data says
Fulgent Genetics, Inc.'s operating margin of -28.2% is lower than 88% of companies in the Health Care sector (FY2025). Operating Margin has declined for 3 consecutive years, from 68.8% in FY2022 to -28.2% in FY2025.
Based on SEC 10-K filings.
-28.2% in FY2025 with a 5-year CAGR of -97.0%.
Declined from 68.1% to -28.2% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- -97.0pp
- 5-Year Change
- -97.0pp
- 10-Year Change
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 148This company -28.2% Sector average -284.8%
▼
+90.1% above sector average
Key checks
Key Insights
- Fulgent Genetics, Inc.'s operating margin has declined for 3 consecutive years.
- In FY2025, operating margin decreased 8.2% year-over-year.
- Currently 256.5pp above the Health Care sector average.
- Peak operating margin was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -28.2% | -8.2% |
| FY2024 | -26.1% | -138.3% |
| FY2023 | 68.1% | -1.0% |
| FY2022 | 68.8% | +5312.1% |
| FY2021 | -1.3% | -101.9% |
| FY2020 | 68.8% | +389.7% |
| FY2019 | -23.8% | -27.8% |
| FY2018 | -18.6% | +71.7% |
| FY2017 | -65.6% | +15.3% |
| FY2016 | -77.5% | -48.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026